FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, in particular to ophthalmology. An agent is applicable for a cross-linking procedure accompanying corneal ectasias. The agent contains riboflavin mononucleotide, chitosan succinate, sodium chloride, tris-(hydroxymethyl)-methylamine, Nipagin, disodium dihydrogen ethylenediaminetetraacetate and purified distilled water in certain proportions.
EFFECT: invention provides prolonged action of the agent, improves bacteriological availability for active ingredients, reduces the length and number of instillations for the procedure, provides agent saving.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 |
|
RU2631604C1 |
| OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 |
|
RU2646452C1 |
| CROSS-LINKING OPHTHALMIC AGENT | 2009 |
|
RU2412707C1 |
| OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 |
|
RU2560669C1 |
| METHOD OF TREATING HERPETIC KERATITIS | 2013 |
|
RU2531426C1 |
| METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 |
|
RU2682494C1 |
| METHOD OF CORNEAL GRAFT PREPARATION FOR LAYER-BY-LAYER KERATOPLASTY | 2019 |
|
RU2723135C1 |
| COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 |
|
RU2676434C1 |
| METHOD OF TREATING EPITHELIAL-ENDOTHELIAL CORNEAL DYSTROPHY | 2019 |
|
RU2703361C1 |
| METHOD OF TREATING KERATOCONUS STAGE I-II | 2022 |
|
RU2819801C2 |
